摘要
目的探讨血清可溶性白细胞介素-2受体(sIL-2R)在恶性实体肿瘤患者中的表现及其临床意义。方法用双抗体夹心酶联免疫吸附试验(ELISA)法对未经系统治疗的各种恶性实体瘤患者,在其治疗前后检测血清sIL-2R,并以体检健康者作健康对照组。结果恶性实体肿瘤患者血清sIL-2R水平均较健康对照组高,一部分肿瘤患者为一般增高,另一部分肿瘤患者为显著增高;大部分肿瘤患者中、后期血清sIL-2R较初期升高显著;术后病情稳定者血清sIL-2R下降明显,手术者较化疗、放疗者下降明显;经手术未见改善者在术后1个月血清sIL-2R仍持续在显著的高水平上。结论检测血清sIL-2R的水平变化,有助于评估恶性实体瘤严重程度、疗效及预后。
Objective To investigate the changes and its clinical meanings about soluble interleukin-2 receptor in serum of malignant entity tumor. Methods The serum levels of .soluble interleukin-2 receptor were detected with ELISA. Before or after the treatment, vein blood, taken out from the patients＇ malignant entity tumor,were examined by this test. Restilts The serum levels of soluble interleukin-2 receptor of malignant entity tumor were abviously higher than that of the healthy. The serum levels of soluble interleukin-2 receptor,most of the patients with cancer at their cancer middle and later period were higher than that in their earlier period. The diseases of the cancer patients after operation were improved in the respect of the soluble interleukin-2 receptor descends obviously. The serum levels of SII. of the cancer patients cured by the surgical operation reduced more than that of the patients cured by the chemistry and were cured by the project line the soluble interleukin-2 receptor descends obviously. Conclusion The patients after operation weren＇t improved, their serum levels of soluble interleukin-2 receptor still kept at the high levels in a month when operated.
出处
《检验医学与临床》
CAS
2009年第11期843-844,共2页
Laboratory Medicine and Clinic
